Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
Rhea-AI Summary
Third Harmonic Bio (Nasdaq: THRD) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Chris Murphy, Chief Financial and Business Officer, will engage in a fireside chat on December 4, 2024, at 9:35 a.m. The company, which focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide a live audio webcast accessible through their website's Investors & Media section. The replay will remain available for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, THRD gained 3.94%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m.
A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archived replay will be accessible for 90 days following the event.
About Third Harmonic Bio, Inc.
Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Early clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a broad range of mast-cell-mediated inflammatory diseases, and that a titratable, oral small molecule inhibitor may provide the optimal therapeutic profile against this target. Third Harmonic Bio’s lead product candidate, THB335, is a titratable, oral, small molecule inhibitor that is currently in a Phase 1 clinical trial. For more information, please visit the Third Harmonic Bio website: www.thirdharmonicbio.com.
Investor and Media Contact:
Lori Murray
lori.murray@thirdharmonicbio.com
FAQ
When is Third Harmonic Bio (THRD) presenting at the Evercore HealthCONx Conference 2024?
How long will the Third Harmonic Bio (THRD) Evercore Conference webcast be available?
What therapeutic areas does Third Harmonic Bio (THRD) focus on?
Who will represent Third Harmonic Bio (THRD) at the 2024 Evercore Conference?
